Schug B S, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume H H
SocraTec R&D GmbH, Feldbergstrasse 59, 61440 Oberursel, Germany.
Eur J Clin Pharmacol. 2002 May;58(2):119-25. doi: 10.1007/s00228-002-0444-7. Epub 2002 Apr 17.
Objective of the study was the comparison of two nifedipine sustained-release products marketed in Europe. Maximum plasma concentration (C(max)) and area under the plasma-concentration curve (AUC) values were derived after administration of single doses (60 mg) of test product and reference product, both approved for once-a-day administration, to 24 healthy male volunteers either after an overnight fast or immediately after a high-fat American breakfast. The study was performed with a randomised, non-blinded, four-period crossover design. Within- and between-product comparisons were determined for fed versus fasted administration considering bioavailability and tolerability of all treatments. Furthermore, in vitro dissolution characteristics of both products were evaluated.
Plasma samples were assayed using a liquid chromatography-mass spectrometry method, and resulting pharmacokinetic parameters were determined model independently according to international requirements and the current European guidelines.
Under fasted conditions the comparison of test and reference products showed a similar extent of bioavailability with a mean ratio of AUC((0-)(infinity)()) of 99% [95% confidence interval (CI) 86%, 114%], but significantly higher C(max) values resulting in a mean ratio of 169% (95% CI 139%, 206%). Accordingly, mean residence time and half-value duration values were smaller for the test product than the reference product. Under fed conditions, a pronounced food effect could be observed for the test product resulting in a pronounced increase of C(max) values. The affiliating point estimate was calculated as 340% with a 95% CI of 279%, 413%. However no remarkable influence of food intake was observed for the reference product.
Under fasting conditions the modified-release characteristics of the test product are less pronounced than the reference product. No relevant impact of food intake could be observed for the reference product when switching from fasted to fed state, whereas a significant loss of modified-release characteristics could be detected for the test product under fed conditions resulting in much higher maximum concentrations. Such a phenomenon has been described in literature as "dose-dumping effect".
本研究的目的是比较两种在欧洲上市的硝苯地平缓释产品。在24名健康男性志愿者中,分别在空腹过夜后或高脂美式早餐后立即给予单次剂量(60毫克)的受试产品和参比产品(两者均批准每日服用一次),然后得出最大血药浓度(C(max))和血药浓度曲线下面积(AUC)值。该研究采用随机、非盲、四周期交叉设计。考虑到所有治疗的生物利用度和耐受性,对进食和空腹给药情况下的产品内和产品间比较进行了测定。此外,还评估了两种产品的体外溶出特性。
采用液相色谱-质谱法测定血浆样本,并根据国际要求和现行欧洲指南独立于模型确定所得的药代动力学参数。
在空腹条件下,受试产品和参比产品的生物利用度程度相似,AUC((0-)(infinity)())的平均比值为99%[95%置信区间(CI)86%,114%],但受试产品的C(max)值显著更高,平均比值为169%(95%CI 139%,206%)。因此,受试产品的平均驻留时间和半衰期值比参比产品小。在进食条件下,可观察到受试产品有明显的食物效应,导致C(max)值显著增加。关联点估计值计算为340%,95%CI为279%,413%。然而,未观察到食物摄入对参比产品有显著影响。
在空腹条件下,受试产品的缓释特性不如参比产品明显。从空腹状态转换到进食状态时,未观察到食物摄入对参比产品有相关影响,而在进食条件下可检测到受试产品的缓释特性显著丧失,导致最高浓度高得多。这种现象在文献中被描述为“剂量倾泻效应”。